Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average

Core Viewpoint - The European Commission has approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide injection) for adults living with obesity, providing an additional option for weight loss after the 2.4 mg dose [1][6]. Group 1: Approval and Dosage Information - The 7.2 mg dosage can be prescribed as three 2.4 mg injections taken in one sitting, still once a week [2]. - Novo Nordisk has applied for approval of a 7.2 mg single-dose pen in the EU, which could be available this year if approved [2]. - Wegovy 7.2 mg is already approved and available in the UK, with regulatory applications pending with the US FDA and other countries [3]. Group 2: Clinical Study Results - In clinical studies STEP UP and STEP UP T2D, participants taking the 7.2 mg dose lost significantly more weight compared to those on placebo [4]. - On average, participants without diabetes lost about 21% of their body weight with Wegovy 7.2 mg, while placebo participants lost about 2% [7]. - Approximately 1 in 3 participants lost 25% or more of their body weight, with 84% of weight loss coming from fat mass while preserving muscle function [7]. Group 3: Product Information and Indications - Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight loss in adults with a BMI of 30 kg/m or greater, or 27 kg/m or greater with weight-related comorbid conditions [5]. - The injectable semaglutide is available in multiple doses: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and now 7.2 mg throughout the EU [4][6].